EGFR and non-small cell lung carcinoma: In the HARMONi trial, the combination of chemotherapy and ivonescimab, a bispecific antibody targeting PD-1 and VEGF, improved PFS compared with chemotherapy alone in patients with EGFR-mutant NSCLC progressing after 3rd-generation TKIs (6.8 vs 4.4 months; HR 0.52, 95% CI 0.41–0.66) [27].